Correlation between lamivudine plasma concentrations and patient self-reported adherence to antiretroviral treatment in experienced HIV patients

Figures & data

Table 1 Predetermined lamivudine (3TC) plasma concentrations in 20 patients who took lamivudine-based adherence to antiretroviral treatment under supervision and blood collected 3 hours after drug intake

Patient	3TC plasma concentrations 3 hours after drug intake in μg/mL
1	0.47
2	0.39
3	0.79
4	0.58
5	0.67
6	2.33
7	0.35
8	0.64
9	0.42
10	0.25
11	0.45
12	0.49
13	1.25
14	0.49
15	0.55
16	0.58
17	1.02
18	0.39
19	0.90
20	0.48
Mean	0.67
Range	0.25–2.33
SD	0.46
CV	69%

Abbreviations: SD, standard deviation; CV, coefficient of variation.

Figure 1 Percentage distribution of patients in relation to obtained lamivudine (3TC) plasma concentrations.

Figure 2 Proportion of patients whose determined lamivudine (3TC) plasma concentrations was in agreement with patient self-report.

Table 2 Proportion of patients (number in brackets) in relation to patient self-report (PSR) and lamivudine (3TC) plasma concentration agreement (n = 200)

3TC plasma concentration in μg/mL	Proportion of patients with agreement between 3TC concentration and PSR	Proportion of patients with disagreement between 3TC concentration and PSR
<0.21 μg/mL	5 (10)	3 (6)
0.21–1.13	51 (102)	3 (6)
>1.13–2.33 μg/mL	25 (50)	5 (10)
>2.33 μg/mL	1.5 (3)	6.5 (13)
Total	82.5 (165)	17.5 (35)